Recent updates and future perspectives about amygdalin as a potential anticancer agent: A review

Jiamin Shi,Qianqian Chen,Meng Xu,Qing Xia,Tiansheng Zheng,Junliang Teng,Ming Li,Lihong Fan
DOI: https://doi.org/10.1002/cam4.2197
IF: 4.711
2019-05-07
Cancer Medicine
Abstract:The overall incidence of cancer is increasing in recent years. Despite advances in various comprehensive treatments, the mortality of advanced malignant tumors remains at a high level. Numerous pharmacological studies have confirmed that many Chinese herbal medicines possess remarkable antitumor activities. Amygdalin, mainly existing in bitter almond, is reported to have antitumor properties in addition to the antioxidative, antibacterial, anti‐inflammatory and immunoregulatory activities. This article summarizes the structural characteristics of amygdalin, its antitumor mechanisms, and recent progress and achievement in the research of amygdalin, hoping that it could provide theoretical clues for exploring the clinical value of amygdalin against tumors. Amygdalin is known to have an antitumor effect in solid tumors such as lung cancer, bladder cancer and renal cell carcinoma by affecting cell cycle, inducing apoptosis and cytotoxicity, and regulating immune function. Further research is needed to elucidate the pharmacological mechanisms of amygdalin in terms of the optimal dosage, the feasibility of combined use of amygdalin with other antitumor drugs, and even artificial synthesis of the active components in amygdalin, for the sake of enhancing its antitumor activities and reducing its adverse effects for clinical use.
oncology
What problem does this paper attempt to address?
The main problem that this paper attempts to solve is to explore the latest progress and future research directions of amygdalin as a potential anticancer agent. Specifically, the paper summarizes the structural characteristics, anticancer mechanisms of amygdalin and its research progress in different cancer types, hoping that these data can provide theoretical clues for exploring the anticancer value of amygdalin in the clinic. The paper mainly focuses on the following aspects: 1. **Structural characteristics of amygdalin**: - Amygdalin is an aromatic aminoglycoside with the molecular formula \( \text{C}_{20}\text{H}_{27}\text{NO}_{11} \) and a molecular weight of 457.43. It contains one benzaldehyde unit, one hydrocyanic acid unit and two glucose units. 2. **Basic anticancer mechanisms of amygdalin**: - **Effect on cell cycle**: Amygdalin affects the cell cycle by regulating cell - cycle - related proteins or genes, and inhibits cell proliferation, especially in prostate cancer and colorectal cancer. - **Induction of apoptosis**: Amygdalin induces apoptosis by increasing Caspase - 3 activity, up - regulating Bax expression and down - regulating Bcl - 2 expression, especially in cervical cancer and prostate cancer. - **Cytotoxic effect**: Amygdalin releases hydrocyanic acid under the action of β - glucosidase, specifically killing tumor cells without obvious toxic side effects on normal cells. - **Immune function regulation**: Amygdalin destroys the tumor microenvironment by enhancing immune function, reducing the levels of immunosuppressive cells or inflammation - related factors, and inhibits tumor immune escape, growth and metastasis. 3. **Latest research progress of amygdalin in different cancer types**: - **Lung cancer**: Amygdalin shows anti - lung cancer effects by inhibiting cell proliferation, invasion and migration, and inhibiting the AKT - mTOR signaling pathway. - **Bladder cancer**: Amygdalin shows anti - bladder cancer effects by inhibiting cell adhesion, migration and cell cycle progression, and reducing the expression of cell cycle - activating factors. - **Renal cell carcinoma**: Amygdalin shows anti - renal cell carcinoma effects by inhibiting cell cycle progression and reducing the expression of cell cycle - related proteins. - **Other cancers**: Amygdalin shows the effects of inhibiting cell proliferation, invasion and metastasis in a variety of malignant tumors. 4. **Current status of clinical research**: - At present, the clinical research on amygdalin is still in the primary stage, lacking high - quality randomized controlled trials (RCTs). The early clinical research results are inconsistent, and more multi - center, placebo - controlled RCTs are needed to evaluate the effectiveness and safety of amygdalin in cancer treatment. In summary, this paper aims to comprehensively summarize the anticancer mechanisms and research progress of amygdalin, and provide a theoretical basis for future clinical applications.